Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amway Corp.

Latest From Vascular Biogenics Ltd.

Deals Shaping The Medical Industry, July 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2016.

BioPharmaceutical Deals

VBL Therapeutics surges on mid-stage cancer results

Gastrointestinal Dermatology

VBL To Test Gene Therapy In Phase III After FDA Lifts Hold

Israeli biotech will commence its Phase III recurrent glioblastoma trial in mid-2015, believes combination therapy with its VB-111 and Avastin can improve overall survival. As it starts its first Phase III trial, VBL also halted work on its lead anti-inflammatory product.

BioPharmaceutical North America

IPO TABLES: Third quarter update, plus three companies price offerings, one sets terms, one files and two postpone

There were 26 initial public offerings by health care companies in the US during the third quarter of 2014, including 19 biotechnology firms, but returns from those offerings were mixed, according to the IPO-tracking firm Renaissance Capital.

Dermatology Neurology
See All